Regeneron Drug Pricing Deal

Regeneron has become the 17th major pharmaceutical company to sign a voluntary price-reduction agreement with the White House.

Under the terms of the deal, the company will significantly cut the price of its cholesterol medications and other high-cost drugs to align with prices paid in other developed nations.

The announcement was made during an Oval Office event where Trump also touted the FDA approval of Regeneron's Otarmeni, the first gene therapy for genetic deafness.

This move is part of a broader effort to provide economic relief to voters ahead of the upcoming midterm elections.